Tel.:
+34 91 736 2385
LOCAL TIME
Contact:
Katarina Gluic
Hours:
Mon-Thu 8:30-17:00 Fri 8:30-15:00
09:36
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
13th International Conference on Malignant Lymphoma
17-20 June 2015 Lugano
About us
FAQs
Help Line
Personal Area
Homepage
Discussion forum -
13th International Conference on Malignant Lymphoma
Topic -
Aggressive B-cell lymphoma
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
Thread / Poster
Author
Replies
Last reply
Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma
Mathias Witzens-Harig
1
6/10/2015 6:00:00 PM
Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies
Arnon Kater
1
6/9/2015 5:18:00 PM
Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi
ANNALISA CHIAPPELLA
1
6/9/2015 12:26:00 AM
Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS)
Annarita Conconi
1
6/9/2015 12:02:00 AM
PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS
Caroline Faes
1
6/8/2015 10:22:00 PM
Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs
BROSÉUS Julien
1
6/8/2015 10:17:00 PM
Molecular characterization of diffuse large B-cell lymphoma recurrences: clonal relationship and different modes of tumor evolution
Darius Juskevicius
1
6/8/2015 8:19:00 PM
Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL- Interim Results from a Nordic Phase II Study
Sirpa Leppa
1
6/8/2015 8:07:00 PM
Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients
Salma Afifi
1
6/8/2015 7:03:00 PM
Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study.
Olivier Casasnovas
1
6/8/2015 5:36:00 PM
Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP
Olivier Casasnovas
1
6/8/2015 4:33:00 PM
RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP
SARA ALONSO ALVAREZ
1
6/7/2015 10:03:00 PM
BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO
MIRIAM LÓPEZ-PARRA
1
6/7/2015 9:29:00 PM
Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype
Michael Gilbertson
1
6/7/2015 8:25:00 AM
Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model
Roopesh Kansara
1
6/6/2015 5:10:00 PM
Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study
Emmanuel Gyan
1
6/6/2015 3:44:00 PM
Prognostic impact of immunohistological profiling in primary CNS lymphoma
Stephan Kreher
1
6/6/2015 12:53:00 PM
Cell of origin is not associated with survival after DLBCL relapse
Umar Farooq
1
6/5/2015 10:05:00 PM
Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL
Alexandra Valera
1
6/5/2015 8:22:00 AM
Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma
Lena Modvig
1
6/4/2015 10:36:00 PM
Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 Alliance)
patrick johnston
1
6/4/2015 8:55:00 PM
NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy
Alexander Deutsch
1
6/2/2015 7:18:00 AM
Analysis of double-hit lymphoma cases by genetic subtype
Chadi Nabhan
1
6/2/2015 4:37:00 AM
The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP
Diego Villa
1
5/30/2015 1:16:00 AM
MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome
Jordina Rovira Sole
1
5/25/2015 3:31:00 PM
MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
Ting-Xun Lu
1
5/23/2015 1:23:00 PM
Most viewed poster for this congress
Poster:
9
Visits:
649
Title:
Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors:
Michael Wang ,
Centre:
The University of Texas MD Anderson Cancer Center
Poster most viewed in this topic
Poster:
154
Visits:
188
Title:
NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy
Authors:
Alexander Deutsch ,
Centre:
Clinical Devision of Hematology
About us
Terms and Conditions
Special Access
Commercial Web Access
Follow us on: